AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03457493
Drug: DPA-714-PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPA-714-PET/MRI
Trial: NCT03457493
Drug: 5-year Follow-up DPA-714-PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/MRI scan with DPA-714
Trial: NCT00209651
Drug: Campto, Topotesin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
Trial: NCT01052467
Drug: Xamiol® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for about 4 weeks
Trial: NCT02686281
Drug: GMC-252-L-Lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02489903
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005960
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005960
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03455335
Drug: 20 million hMSCs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03455335
Drug: 40 million hMSCs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01129570
Drug: Silybin
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
Trial: NCT03455335
Drug: 80 million hMSCs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01041729
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment.
Trial: NCT02818491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% in 2 mls
Trial: NCT02730208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to TEZ/IVA fixed-dose combination tablet.
Trial: NCT02730208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to IVA tablet.
Trial: NCT02789332
Drug: PwO
RxNorm normalized name: Tilia sapwood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
Trial: NCT02789332
Drug: PwCb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
Trial: NCT00626054
Drug: PEG solution in a single dose of 3 liters
RxNorm normalized name: PEG-3 cocamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
Trial: NCT02310646
Drug: Daivobet® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
Trial: NCT01902134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single oral dose (first 8 hours)
Trial: NCT01902134
Drug: Dexketoprofen-single dose
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen single oral dose (first 8 hours)
Trial: NCT01902134
Drug: Dexketoprofen/Tramadol-single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen/Tramadol oral single dose (first 8 hours)
Trial: NCT01902134
Drug: Dexketoprofen-multiple doses
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
Trial: NCT01902134
Drug: Dexketoprofen/Tramadol-multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Trial: NCT02543086
Drug: KAE609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug
Trial: NCT02379793
Drug: LEO 80185 gel, vehicle, liquid paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
Trial: NCT04151342
Drug: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
Trial: NCT02812355
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00371007
Drug: Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04749810
Drug: Elizaria®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
Trial: NCT03627195
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection
Trial: NCT04095390
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg
Trial: NCT02601911
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
Trial: NCT04564742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
Trial: NCT01188954
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 ml/mg
Trial: NCT02715479
Drug: BMS955176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS955176
Trial: NCT01400854
Drug: Effentora®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
Trial: NCT02666534
Drug: methyl-aminolevulinate application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Trial: NCT03313076
Drug: Omega-3 fatty acid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
Trial: NCT05102045
Drug: Acetylcholinesterase Inhibitors
RxNorm normalized name: acetylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
Trial: NCT00742482
Drug: HL 10
RxNorm normalized name: benzocaine/benzalk chl 10 %-0.13 % TOPICAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze dried HL 10
Trial: NCT04115306
Drug: PMD-026
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Drug
Trial: NCT03089554
Drug: Therapeutic Intervention
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Intervention
Trial: NCT03634332
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
Trial: NCT04006847
Drug: Tyrosine kinase inhibitor
RxNorm normalized name: Protein-tyrosine kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
Trial: NCT02292433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, breakfast plus lunch, 7 days
Trial: NCT01082445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04510220
Drug: [F-18]PBR06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
Trial: NCT00625742
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg by mouth (PO) Daily
Trial: NCT00625742
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1200mg/day in three divided doses.
Trial: NCT01081262
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04542499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Trial: NCT00850161
Drug: Nasulin™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU(2 puffs in each nostril)
Trial: NCT03954041
Drug: BIIB093
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03954041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT00382291
Drug: Regular Titration
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
Trial: NCT00382291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
Trial: NCT00382291
Drug: Slow Titration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
Trial: NCT01498419
Drug: Rifafour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
Trial: NCT01270841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule 1x daily for 3 months
Trial: NCT04551079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-994 placebo-matching tablets.
Trial: NCT01110499
Drug: AGN-210961 Formulation 1
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210961 Formulation 1 in one eye once daily for 7 days.
Trial: NCT01869491
Drug: Matching placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets four times daily
Trial: NCT01110499
Drug: AGN-210961 Formulation 2
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210961 Formulation 2 in one eye once daily for 7 days.
Trial: NCT01110499
Drug: AGN-210961 Formulation 3
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210961 Formulation 3 in one eye once daily for 7 days.
Trial: NCT01110499
Drug: AGN-210961 Formulation 5
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210961 Formulation 5 in one eye once daily for 7 days.
Trial: NCT03958565
Drug: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
RxNorm normalized name: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Q4 weeks as standard of care
Trial: NCT01110499
Drug: AGN-210961 Formulation 6
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210961 Formulation 6 in one eye once daily for 7 days.
Trial: NCT01110499
Drug: AGN-210961 Formulation 7
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
Trial: NCT00769899
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral, single dose
Trial: NCT00769899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for oral, single dose
Trial: NCT02544633
Drug: MGCD265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
Trial: NCT01337687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
Trial: NCT01224756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
Trial: NCT03405337
Drug: FVIII products
RxNorm normalized name: factor VIII Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adynovate, Eloctate, Afstyla, Kovaltry
Trial: NCT01410539
Drug: OCT guided medical therapy
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCT guided medical therapy. Tailored antiplatelet therapy.
Trial: NCT03524937
Drug: MELATONIN (HIGH DOSE)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
Trial: NCT03524937
Drug: MELATONIN (LOW DOSE)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
Trial: NCT03524937
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
Trial: NCT00715169
Drug: MLN1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
Trial: NCT02597634
Drug: SST-0225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
Trial: NCT00409188
Drug: Single low dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
Trial: NCT00409188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
Trial: NCT04410536
Drug: Symptomatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
Trial: NCT04410536
Drug: Bridge therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
Trial: NCT02650505
Drug: LEO 43204
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02650505
Drug: LEO 43204 Vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02597634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Trial: NCT01033656
Drug: comparators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po drugs, comparators
Trial: NCT00845754
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg IV every6 hours for 4doses
Trial: NCT03066154
Drug: androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT according to the standard of care
Trial: NCT02684487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
Trial: NCT02214498
Drug: Enalapril/hydrochlorothiazide
RxNorm normalized name: ENALAPRIL/HYDROCHLOROTHIAZIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
Trial: NCT01406925
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream
Trial: NCT01406925
Drug: NRL001 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream for single-dose intra-anal application
Trial: NCT02316912
Drug: ATX2417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised double blind parallel group ascending dose assessment
Trial: NCT02316912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised double blind parallel group ascending dose assessment
Trial: NCT04176887
Drug: Phenytoin Injection
RxNorm normalized name: phenytoin Injection
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
Trial: NCT01363388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID for 84 days
Trial: NCT01363388
Drug: CCX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID for 84 days
Trial: NCT03988413
Drug: 400mg
RxNorm normalized name: MESNA 400MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 400mg or Placebo 400mg
Trial: NCT04378010
Drug: EDP-305 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04378010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01792284
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03601000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules 5g given three times a day for up to 16 weeks.
Trial: NCT03149393
Drug: Qizhi Weitong Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
Trial: NCT02537574
Drug: NTX/BUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily doses
Trial: NCT02537574
Drug: NTX/PBO-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily doses
Trial: NCT02537574
Drug: PBO-N/PBO-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily doses
Trial: NCT02663687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo
Trial: NCT02663687
Drug: SHP623
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP623
Trial: NCT02663687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03580239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
Trial: NCT04394182
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/24h, 3 days
Trial: NCT04394182
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prophylactic doses
Trial: NCT04394182
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg x 3 boluses
Trial: NCT00112697
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03931668
Drug: TPN-672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of TPN-672 maleate tablet
Trial: NCT01880047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00926068
Drug: HO/03/03 10µg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00926068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no